CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION
3.2. NEED FOR GLUCOSE MONITORING SYSTEMS

3.2.1. Diabetesa pandemic

3.2.1.1. Type 1 diabetes
3.2.1.2. Type-2 diabetes
3.2.1.3. Prediabetes and gestational diabetes mellitus (GDM)
3.2.1.4. Gestational diabetes mellitus (GDM)
3.2.1.5. Secondary diabetes
3.2.1.6. Global healthcare expenditure on diabetes

3.3. TECHNOLOGICAL ADVANCEMENTS IN CGMS

3.3.1. Smartphone-connected CGMS

3.3.1.1 Wearable and smartphone-connected CGMS
3.3.1.2. 'Smart diabetes management solutionbionic/artificial pancreas
3.3.1.3. Non-invasive CGMS
3.3.1.4. Invasive CGMS

3.3.2. CGMS: PRIME END USER SEGMENTS

3.3.2.1. CGMS: role in intensive care units (ICUs)

3.3.2.1.1. Stress hyperglycemia: common occurrence in ICUs

3.3.2.2. Non-standardization and erroneous glycemic control across ICUs
3.3.2.3. Benefits and driving factors of CGMS in ICUs

3.3.2.3.1. Use of CGMS for tight glycemic control in ICUs
3.3.2.3.2. Cost benefits due to use of CGMS
3.3.2.3.3. Lower effectiveness of POC glucometers than CGMS in ICUs
3.3.2.3.4. CGMS: most preferred by ICU staff

3.4. KEY FINDINGS

3.4.1. Top investment pockets

3.4.1.1. CGMS market, by components

3.4.2. Top winning strategies

3.5. PATENT ANALYSIS
3.6. MARKET SHARE ANALYSIS, 2015
3.7. GOVERNMENT REGULATIONS

3.7.1. ISO regulations (ISO 13485:2003)

3.7.1.1. Objective and Scope of ISO 13485:2003

3.8. EUROPE REIMBURSEMENT SCENARIO

3.8.1. Germany
3.8.2. France
3.8.3. UK
3.8.4. Spain
3.8.5. Italy

3.9. MARKET DYNAMICS

3.9.1. Drivers

3.9.1.1. Benefits of CGMS over POC glucometers
3.9.1.2. Rise in incidence of diabetes cases
3.9.1.3. Technological advancements

3.9.2. Restraints

3.9.2.1. Adverse effects and accuracy
3.9.2.2. Reimbursement and stringent regulatory issues

3.9.3. Opportunities

3.9.3.1. High adoption rate of CGMS in home healthcare and ICUs
3.9.3.2. Increase in product awareness
3.9.3.3. High undiagnosed patient population

CHAPTER 4 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SENSORS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. TRANSMITTERS & RECEIVERS

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. INTEGRATED INSULIN PUMPS

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKETBY DEMOGRAPHICS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ADULT POPULATION (>14 YEARS)

5.2.1. Market size and forecast

5.3. CHILDREN POPULATION (14 YEARS)

5.3.1. Market size and forecast

CHAPTER 6 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. DIAGNOSTIC CENTERS/CLINICS

6.2.1. Market size and forecast

6.3. ICUS

6.3.1. Market size and forecast

6.4. HOME HEALTHCARE

6.4.1. Market size and forecast

CHAPTER 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY

7.1. OVERVIEW

7.1.1. Key market trends
7.1.2. Key growth factors and opportunities
7.1.3. Market size and forecast
7.1.4. Germany

7.1.4.1. Market size and forecast

7.1.5. France

7.1.5.1. Market size and forecast

7.1.6. UK

7.1.6.1. Market size and forecast

7.1.7. Spain

7.1.7.1. Market size and forecast

7.1.8. Italy

7.1.8.1. Market size and forecast

7.1.9. Norway

7.1.9.1. Market size and forecast

7.1.10. Sweden

7.1.10.1. Market size and forecast

7.1.11. Denmark

7.1.11.1. Market size and forecast

7.1.12. Finland

7.1.12.1. Market size and forecast

7.1.13. Netherlands

7.1.13.1. Market size and forecast

7.1.14. Rest of Europe

7.1.14.1. Market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1. Overview
8.1.2. Operating business segments
8.1.3. Business performance
8.1.4. Key strategic moves and developments

8.2. DEXCOM, INC.

8.2.1. Overview
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. ECHO THERAPEUTICS, INC.

8.3.1. Overview
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. F. HOFFMANN-LA ROCHE LTD.

8.4.1. Overview
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. INSULET CORPORATION

8.5.1. Overview
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.6. JOHNSON & JOHNSON

8.6.1. Overview
8.6.2. Operating business segments
8.6.3. Business performance
8.6.4. Key strategic moves and developments

8.7. MEDTRONIC PLC

8.7.1. Overview
8.7.2. Operating business segments
8.7.3. Business performance
8.7.4. Key strategic moves and developments

8.8. SENSEONICS HOLDINGS, INC.

8.8.1. Overview
8.8.2. Key strategic moves and developments